|
Vertex’s Groundbreaking CF Drug Kalydeco Gets EMA Nod as Company Backpedals on New CF Trial Data
The European Medicines Agency (EMA) is recommending approval of Vertex Pharmaceuticals’ cystic fibrosis (CF) treatment Kalydeco as the first drug to address the underlying cause of the life-threating genetic disorder.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives